SAGE Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good afternoon, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have Sage Therapeutics with us.
Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures.
And with that, pleased to turn it over to Barry Greene, the CEO, to make some opening comments and then we'll jump into Q&A.
Great. Thanks, Matthew, and especially thanks to Morgan Stanley for having us today. It really is an exciting time at Sage, and I'm thrilled with the substantial progress we've made so far this year, which is in line with the goals we laid out at the beginning of the year to expand and accelerate our pipeline
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |